Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S Trading Up 3.7 %
ASND traded up $3.36 during trading on Friday, hitting $94.91. 1,148,305 shares of the stock were exchanged, compared to its average volume of 317,097. The firm has a 50 day simple moving average of $88.09 and a 200 day simple moving average of $100.67. The firm has a market cap of $5.41 billion, a price-to-earnings ratio of -10.14 and a beta of 0.68. Ascendis Pharma A/S has a 1 year low of $61.58 and a 1 year high of $178.71. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.79 and a current ratio of 11.76.
Ascendis Pharma A/S (NASDAQ:ASND - Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($2.25) by ($0.23). The firm had revenue of $7.66 million for the quarter, compared to analysts' expectations of $5.89 million. Ascendis Pharma A/S had a negative return on equity of 54.58% and a negative net margin of 3,281.45%. During the same quarter in the previous year, the business earned ($1.41) earnings per share. As a group, equities analysts expect that Ascendis Pharma A/S will post -8.86 EPS for the current year.
Analyst Ratings Changes
ASND has been the subject of several analyst reports. Citigroup lowered their price objective on Ascendis Pharma A/S from $187.00 to $158.00 in a research note on Thursday, May 12th. Cantor Fitzgerald lowered their price objective on Ascendis Pharma A/S from $230.00 to $180.00 in a research note on Thursday, May 12th. Credit Suisse Group decreased their price target on Ascendis Pharma A/S from $194.00 to $123.00 in a research note on Thursday, May 12th. Oppenheimer decreased their price target on Ascendis Pharma A/S from $166.00 to $154.00 in a research note on Thursday, May 12th. Finally, Wells Fargo & Company decreased their price target on Ascendis Pharma A/S from $190.00 to $176.00 in a research note on Thursday, May 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and an average price target of $163.40.